title: Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
abstract: This study was performed to identify whether cytogenetics, International Prognostic Scoring System (IPSS), or World Health Organization Classification-Based Prognostic Scoring System are predictive of the efficacy of azacitidine in patients with myelodysplastic syndrome (MDS). We retrospectively reviewed the clinical records of 113 patients with MDS treated with azacitidine. The "response alternating disease natural history," "cytogenetic response," and "hematologic improvement" were assessed by serial bone marrow biopsy, cytogenetic study, and hemogram analyses. The complete and partial remission rates were 17.6% and 3.9% in 51 evaluable patients. There were no significant differences in response rate in the different cytogenetic/IPSS/WPSS groups. The overall hematologic response (HR) rate was 49.6%, and the HR rate was significantly greater in patients classed as "very high" risk according to the WPSS compared with other patient groups. The 1-year overall survival (OS) rate was higher among patients with HR compared with those without HR (80.9% vs 63.3%, p = 0.046), and the 1-year OS rate among patients classed as being at high risk by each criteria was similar to that of patients classed as being at low risk. The hazard ratio of death among patients with HR compared with those without HR was 0.17 (95% CI 0.04-0.69) for high + very high risk group based on WPSS. Patients in the WPSS high-risk group had an increased HR rate compared with other patient groups, and the achievement of HR was associated with a significant increase in OS. Azacitidine showed similar efficacy in all patient groups, even in patients with poor cytogenetics and in high-risk groups.
authors: Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors: Dae-Young
authors: DY
authors: Kim
authors: Je-Hwan
authors: JH
authors: Lee
authors: Jung-Hee
authors: JH
authors: Lee
authors: Kyoo-Hyung
authors: KH
authors: Lee
authors: Yoe-Kyeoung
authors: YK
authors: Kim
authors: Jae Sook
authors: JS
authors: Ahn
authors: Hyeoung-Joon
authors: HJ
authors: Kim
authors: Inho
authors: I
authors: Kim
authors: Sung-Soo
authors: SS
authors: Yoon
authors: Seonyang
authors: S
authors: Park
authors: Sung Hwa
authors: SH
authors: Bae
authors: Soo-Mee
authors: SM
authors: Bang
authors: Hong Ghi
authors: HG
authors: Lee
authors: Ho-Jin
authors: HJ
authors: Shin
authors: Jae Hoon
authors: JH
authors: Lee
authors: Yoo Hong
authors: YH
authors: Min
authors: Jong-Ho
authors: JH
authors: Won
authors: Yeung-Chul
authors: YC
authors: Mun
authors: Doyeun
authors: D
authors: Oh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine